Last reviewed · How we verify
D-4517.2
At a glance
| Generic name | D-4517.2 |
|---|---|
| Also known as | aflibercept |
| Sponsor | Ashvattha Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME (PHASE2)
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |